Loading...
Market
Age group with highest adoption rate of FluMist nasal spray vaccine by end of 2024?
2
Resolution / Starting Odds
2-12 years • 25%
13-24 years • 25%
25-49 years • 25%
Evenly distributed • 25%
Market research reports or AstraZeneca usage data
Story
FDA Approves First At-Home FluMist for Self- or Caregiver-Administration
Sep 20, 2024, 06:34 PM
The U.S. Food and Drug Administration (FDA) has approved AstraZeneca's FluMist nasal spray vaccine for self- or caregiver-administration, making it the first influenza vaccine that can be administered at home without the need for a healthcare provider. The vaccine is approved for individuals aged 2 through 49 years and aims to expand consumer access to medicines, reduce costs, and lower barriers to care. This approval represents a significant step in broadening vaccination options and enhancing public health measures. Interested individuals will complete a screening and eligibility assessment through a third-party pharmacy.
View original story
Similar markets
2-12 years • 25%
13-24 years • 25%
25-35 years • 25%
36-49 years • 25%
2-18 years • 25%
19-29 years • 25%
30-49 years • 25%
All age groups equally • 25%
2-12 years • 25%
13-24 years • 25%
25-49 years • 25%
50+ years • 25%
2-12 years • 25%
13-24 years • 25%
25-34 years • 25%
35-49 years • 25%
2-12 years • 25%
13-24 years • 25%
25-49 years • 25%
Evenly distributed • 25%
2-12 years • 25%
13-29 years • 25%
30-49 years • 25%
Equal uptake across all age groups • 25%
2-12 years • 25%
13-24 years • 25%
25-34 years • 25%
35-49 years • 25%
Children (6 months to 11 years) • 25%
Adolescents (12 to 17 years) • 25%
Adults (18 to 64 years) • 25%
Seniors (65 years and older) • 25%
18-24 • 25%
25-34 • 25%
35-44 • 25%
45+ • 25%
Northeast • 25%
South • 25%
Midwest • 25%
West • 25%
12-17 years • 25%
18-29 years • 25%
30-49 years • 25%
50+ years • 25%
18-34 years • 25%
35-49 years • 25%
50-64 years • 25%
65+ years • 25%